FibroBiologics (FBLG) Set to Post Earnings on Friday

FibroBiologics (NASDAQ:FBLG) is expected to be releasing its Q3 2026 results before the market opens on Friday, October 30th. Analysts expect FibroBiologics to announce earnings of ($0.63) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 6, 2026 at 3:00 PM ET.

FibroBiologics (NASDAQ:FBLG) last posted its quarterly earnings results on Friday, July 31st. The company reported ($0.66) EPS for the quarter, topping analysts’ consensus estimates of ($0.93) by $0.27. On average, analysts expect FibroBiologics to post ($3.00) EPS for the current fiscal year and ($3.25) EPS for the next fiscal year.

FibroBiologics Price Performance

FBLG stock opened at $0.97 on Thursday. FibroBiologics has a 1-year low of $0.62 and a 1-year high of $9.60. The company has a market capitalization of $6.44 million, a price-to-earnings ratio of -0.19 and a beta of 1.72. The business has a 50 day simple moving average of $1.32 and a two-hundred day simple moving average of $2.49.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $6.00 price objective (down from $8.00) on shares of FibroBiologics in a research report on Tuesday, August 4th. Deutsche Bank Aktiengesellschaft lowered shares of FibroBiologics to an “underperform” rating in a research report on Tuesday, August 4th. Weiss Ratings upgraded shares of FibroBiologics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, September 4th. Finally, Wall Street Zen raised shares of FibroBiologics to a “hold” rating in a research note on Saturday, October 10th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, FibroBiologics has a consensus rating of “Reduce” and a consensus target price of $73.00.

FibroBiologics Company Profile

FibroBiologics, Inc is a clinical-stage biotechnology company developing cell-based therapies for chronic diseases. Its research focuses on fibroblasts, connective-tissue cells that may support tissue repair and influence immune-system activity, as well as biologically active materials derived from these cells.

The company is developing a platform that includes fibroblast-based cell therapies and fibroblast-derived extracellular vesicles. These potential treatments are intended to address conditions involving chronic inflammation, immune dysfunction, and tissue damage.